Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 12:36 AM
Ignite Modification Date: 2025-12-25 @ 12:36 AM
NCT ID: NCT04167267
Eligibility Criteria: Inclusion Criteria: * Healthy adult aged between 19 and 45 at screening * Those whose weight is 55 kg and more and BMI is between 17.5 and 30.5 kg/m2 * Subjects who are adequate to be subjects in this study upon judgment of the investigator after physical examination, clinical laboratory test, examination by interview, etc Exclusion Criteria: * Subjects who have clinical significant liver, kidney, nervous system, respiratory, endocrine, hematology and oncology, cardiovascular, urinary, and mental diseases or past history * Subjects who have gastrointestinal diseases or past history of gastrointestinal diseases (gastrointestinal ulcer, gastritis, gastrospasm, gastroesophageal reflux, Crohn's disease etc.) that may affect safety and pharmacokinetic/pharmacodynamic evaluation of study drug, and those who have past history of gastrointestinal surgery (however, except simple ppendectomy and herniotomy) * Subjects who showed positive result for Helicobacter pylori test * Subjects with serum AST (SGOT) or ALT (SGPT) level \>1.5 times the upper limit of the normal range at the time of the screening examination * Subjects with a history of drug abuse or a positive urine screening for drug abuse * Subjects who have participated and taken investigational drug in any other clinical trial (including bioequivalence study) within six months prior to study drug administration * Subjects who have donated a unit of whole blood within two months or blood components within one month prior to study drug administration
Healthy Volunteers: True
Sex: ALL
Minimum Age: 19 Years
Maximum Age: 45 Years
Study: NCT04167267
Study Brief:
Protocol Section: NCT04167267